68Ga-NTA-476(68Ga-NTA-476) - 药物靶点：PSMA_在研适应症：前列腺癌_专利_临床

概要

基本信息

药物类型

诊断用放射药物、核素偶联药物

别名-

靶点

PSMA

作用机制

PSMA调节剂(前列腺癌特异性膜抗原调节剂)、PET imaging(正电子发射断层成像术增强剂)

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

前列腺癌

非在研适应症-

原研机构

3B Pharmaceuticals GmbH

在研机构

3B Pharmaceuticals GmbH

非在研机构-

最高研发阶段早期临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

3

项与 68Ga-NTA-476 相关的临床试验

ACTRN12623001157662 / Recruiting早期临床1期

Uptake, Safety and Tolerability of 68Ga-NTA-476 Imaging of Prostate Cancer Tumours

开始日期2024-08-16

申办/合作机构

Genesis Care Pty Ltd.

ACTRN12624000935538 / Not yet recruiting早期临床1期IIT

A Single-Arm Comparative Imaging study to evaluate the uptake of 68Ga-NTA-476 on PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men with Prostate Cancer

开始日期2024-08-14

申办/合作机构-

NCT06520449 / Not yet recruiting早期临床1期IIT

A Single-Arm Comparative Imaging Study of 68Ga-NTA-476 PET/CT Compared to Standard of Care 18F-DCFPyL PET/CT in Men With Prostate Cancer

This study is investigating a new agent to be used in PET imaging for prostate cancer, called 68Ga-NTA-476. It aims to find out where 68Ga-NTA-476 goes in the body once it is injected into a person and whether there are any side effects or issues with tolerating the compound. This will be compared to an existing imaging compound which is currently used in Australia called 18F-DCFPyl. 68Ga-NTA-476 has been developed and tested in the laboratory; however, this is the first time that it will be tested in humans.

开始日期2024-08-01

申办/合作机构